Obesity and cancer mechanisms: Cancer metabolism

Journal of Clinical Oncology

Volumn 34, Issue 35, 2016, Pages 4277-4283

  Hopkins, Benjamin D ^a   Goncalves, Marcus D ^a   Cantley, Lewis C ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPOCYTOKINE; CARBOHYDRATE; INSULIN; METFORMIN; SOMATOMEDIN; STEROID HORMONE; TUMOR MARKER;

CALORIC RESTRICTION; CANCER RISK; CARBOHYDRATE INTAKE; CLINICAL TRIAL; DRUG USE; HUMAN; MALIGNANT NEOPLASM; OBESITY; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; COMPLICATION; DISEASE COURSE; ENERGY METABOLISM; METABOLISM; NEOPLASM; PROGNOSIS; RISK FACTOR; TUMOR MICROENVIRONMENT;

BIOMARKERS, TUMOR; DISEASE PROGRESSION; ENERGY METABOLISM; HUMANS; NEOPLASMS; OBESITY; PROGNOSIS; RISK FACTORS; SIGNAL TRANSDUCTION; TUMOR MICROENVIRONMENT;

EID: 85002584774     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2016.67.9712     Document Type: Review

References (128)

1. Hanahan D, Weinberg RA: The hallmarks of cancer. Cell 100:57-70, 2000
2. Flegal KM, Carroll MD, Kit BK, et al: Prevalence of obesity and trends in the distribution of bodymass index among US adults, 1999-2010. JAMA 307:491-497, 2012
3. Finucane MM, Stevens GA, Cowan MJ, et al: National, regional, and global trends in body-mass index since 1980: Systematic analysis of health examination surveys and epidemiological studies with 960 country-years and 9.1 million participants. Lancet 377:557-567, 2011
4. Ogden CL, Carroll MD, Kit BK, et al: Prevalence of childhood and adult obesity in the United States, 2011-2012. JAMA 311:806-814, 2014
5. Hursting SD, Digiovanni J, Dannenberg AJ, et al: Obesity, energy balance, and cancer: New opportunities for prevention. Cancer Prev Res (Phila) 5:1260-1272, 2012
6. Bhaskaran K, Douglas I, Forbes H, et al: Bodymass index and risk of 22 specific cancers: A population-based cohort study of 5.24 million UK adults. Lancet 384:755-765, 2014
7. Calle EE, Rodriguez C, Walker-Thurmond K, et al: Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U. S. adults. N Engl J Med 348:1625-1638, 2003
8. Prado CM, Cushen SJ, Orsso CE, et al: Sarcopenia and cachexia in the era of obesity: Clinical and nutritional impact. Proc Nutr Soc 75:188-198, 2016
9. Martin L, Birdsell L, Macdonald N, et al: Cancer cachexia in the age of obesity: Skeletal muscle depletion is a powerful prognostic factor, independent of body mass index. J Clin Oncol 31:1539-1547, 2013
10. Engelman JA, Cantley LC: Chemoprevention meets glucose control. Cancer Prev Res (Phila) 3:1049-1052, 2010
11. Hsu PP, Sabatini DM: Cancer cell metabolism: Warburg and beyond. Cell 134:703-707, 2008
12. Vander Heiden MG, Cantley LC, Thompson CB: Understanding the Warburg effect: The metabolic requirements of cell proliferation. Science 324:1029-1033, 2009
13. Ferguson RD, Novosyadlyy R, Fierz Y, et al: Hyperinsulinemia enhances c-Myc-mediated mammary tumor development and advances metastatic progression to the lung in a mouse model of type 2 diabetes. Breast Cancer Res 14:R8, 2012
14. Yoon YS, Keum N, Zhang X, et al: Hyperinsulinemia, insulin resistance and colorectal adenomas: A meta-analysis. Metabolism 64:1324-1333, 2015
15. Hernandez AV, Pasupuleti V, Benites-Zapata VA, et al: Insulin resistance and endometrial cancer risk: A systematic review and meta-analysis. Eur J Cancer 51:2747-2758, 2015
16. Hammarsten J, Högstedt B: Hyperinsulinaemia: A prospective risk factor for lethal clinical prostate cancer. Eur J Cancer 41:2887-2895, 2005
17. Gunter MJ, Hoover DR, Yu H, et al: Insulin, insulin-like growth factor-I, and risk of breast cancer in postmenopausal women. J Natl Cancer Inst 101:48-60, 2009
18. Kalaany NY, Sabatini DM: Tumours with PI3K activation are resistant to dietary restriction. Nature 458:725-731, 2009
19. Guo JY, White E: Autophagy is required for mitochondrial function, lipid metabolism, growth, and fate of KRAS (G12D)-driven lung tumors. Autophagy 9:1636-1638, 2013
20. Harris FT, Rahman S M J, Hassanein M, et al: Acyl-coenzyme A-binding protein regulates Betaoxidation required for growth and survival of nonsmall cell lung cancer. Cancer Prev Res (Phila) 7:748-757, 2014
21. Rodŕýguez-Enŕýquez S, Herńandez-Esquivel L, Maŕýn-Herńandez A, et al: Mitochondrial free fatty acid b-oxidation supports oxidative phosphorylation and proliferation in cancer cells. Int J Biochem Cell Biol 65:209-221, 2015
22. Schlaepfer IR, Rider L, Rodrigues LU, et al: Lipid catabolism via CPT1 as a therapeutic target for prostate cancer. Mol Cancer Ther 13:2361-2371, 2014
23. Nieman KM, Kenny HA, Penicka CV, et al: Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth. Nat Med 17:1498-1503, 2011
24. Nieman KM, Romero IL, Van Houten B, et al: Adipose tissue and adipocytes support tumorigenesis and metastasis. Biochim Biophys Acta 1831:1533-1541, 2013
25. Friedman JM, Halaas JL: Leptin and the regulation of body weight in mammals. Nature 395:763-770, 1998
26. Saxena NK, Vertino PM, Anania FA, et al: Leptin-induced growth stimulation of breast cancer cells involves recruitment of histone acetyltransferases and mediator complex to CYCLIN D1 promoter via activation of Stat3. J Biol Chem 282:13316-13325, 2007
27. Nimri L, Saadi J, Peri I, et al: Mechanisms linking obesity to altered metabolism in mice colon carcinogenesis. Oncotarget 6:38195-38209, 2015
28. 2-terminal kinase. J Biol Chem 278:42660-42667, 2003
29. Garofalo C, Surmacz E: Leptin and cancer. J Cell Physiol 207:12-22, 2006
30. Fazolini NP, Cruz AL, Werneck MB, et al: Leptin activation of mTOR pathway in intestinal epithelial cell triggers lipid droplet formation, cytokine production and increased cell proliferation. Cell Cycle 14:2667-2676, 2015
31. Fenton JI, Hursting SD, Perkins SN, et al: Interleukin-6 production induced by leptin treatment promotes cell proliferation in an Apc (Min/+) colon epithelial cell line. Carcinogenesis 27:1507-1515, 2006
32. Nomura S, Sakamaki S, Hongu M, et al: Discovery of canagliflozin, a novel C-glucoside with thiophene ring, as sodium-dependent glucose cotransporter 2 inhibitor for the treatment of type 2 diabetes mellitus. J Med Chem 53:6355-6360, 2010
33. Grossmann ME, Nkhata KJ, Mizuno NK, et al: Effects of adiponectin on breast cancer cell growth and signaling. Br J Cancer 98:370-379, 2008
34. Cong L, Gasser J, Zhao J, et al: Human adiponectin inhibits cell growth and induces apoptosis in human endometrial carcinoma cells, HEC-1-A and RL95 2. Endocr Relat Cancer 14:713-720, 2007
35. Bub JD, Miyazaki T, Iwamoto Y: Adiponectin as a growth inhibitor in prostate cancer cells. Biochem Biophys Res Commun 340:1158-1166, 2006
36. Housa D, Housová J, Vernerov á Z, et al: Adipocytokines and cancer. Physiol Res 55:233-244, 2006
37. Yamaji T, Iwasaki M, Sasazuki S, et al: Interaction between adiponectin and leptin influences the risk of colorectal adenoma. Cancer Res 70:5430-5437, 2010
38. Cleary MP, Grossmann ME: Minireview: Obesity and breast cancer: The estrogen connection. Endocrinology 150:2537-2542, 2009
39. Reeves GK, Pirie K, Beral V, et al: Cancer incidence and mortality in relation to body mass index in the Million Women Study: Cohort study. BMJ 335:1134, 2007
40. Yager JD, Davidson NE: Estrogen carcinogenesis in breast cancer. N Engl JMed 354:270-282, 2006
41. Péqueux C, Raymond-Letron I, Blacher S, et al: Stromal estrogen receptor-a promotes tumor growth by normalizing an increased angiogenesis. Cancer Res 72:3010-3019, 2012
42. Kaaks R, Lukanova A, Kurzer MS: Obesity, endogenous hormones, and endometrial cancer risk: A synthetic review. Cancer Epidemiol Biomarkers Prev 11:1531-1543, 2002
43. Lonergan PE, Tindall DJ: Androgen receptor signaling in prostate cancer development and progression. J Carcinog 10:20, 2011
44. Rondini EA, Harvey AE, Steibel JP, et al: Energy balance modulates colon tumor growth: Interactive roles of insulin and estrogen. Mol Carcinog 50:370-382, 2011
45. Hursting SD, Berger NA: Energy balance, hostrelated factors, and cancer progression. J Clin Oncol 28:4058-4065, 2010
46. Jiang W, Zhu Z, Bhatia N, et al: Mechanisms of energy restriction: Effects of corticosterone on cell growth, cell cycle machinery, and apoptosis. Cancer Res 62:5280-5287, 2002
47. Allan CA, McLachlan RI: Androgens and obesity. Curr Opin Endocrinol Diabetes Obes 17:224-232, 2010
48. Salehi M, Ferenczi A, Zumoff B: Obesity and cortisol status. Horm Metab Res 37:193-197, 2005
49. Dong MQ, Venable JD, Au N, et al: Quantitative mass spectrometry identifies insulin signaling targets in C. elegans. Science 317:660-663, 2007
50. White MF, Kahn CR: The insulin signaling system. J Biol Chem 269:1-4, 1994
51. Ruderman NB, Kapeller R, White MF, et al: Activation of phosphatidylinositol 3-kinase by insulin. Proc Natl Acad Sci USA 87:1411-1415, 1990
52. Li N, Batzer A, Daly R, et al: Guaninenucleotidereleasing factor hSos1 binds to Grb2 and links receptor tyrosine kinases to Ras signalling. Nature 363:85-88, 1993
53. 3 protein is required for p21Ras1 activation and binds to sevenless and Sos proteins in vitro. Cell 73:169-177, 1993
54. Gallagher EJ, LeRoith D: Minireview: IGF, insulin, and cancer. Endocrinology 152:2546-2551, 2011
55. Papa V, Pezzino V, Costantino A, et al: Elevated insulin receptor content in human breast cancer. J Clin Invest 86:1503-1510, 1990
56. Mathieu MC, Clark GM, Allred DC, et al: Insulin receptor expression and clinical outcome in nodenegative breast cancer. Proc Assoc Am Physicians 109:565-571, 1997
57. Law JH, Habibi G, Hu K, et al: Phosphorylated insulin-like growth factor-I/insulin receptor is present in all breast cancer subtypes and is related to poor survival. Cancer Res 68:10238-10246, 2008
58. Frasca F, Pandini G, Scalia P, et al: Insulin receptor isoform A, a newly recognized, high-affinity insulin-like growth factor II receptor in fetal and cancer cells. Mol Cell Biol 19:3278-3288, 1999
59. Flannery CA, Saleh FL, Choe GH, et al: Differential expression of IR-A, IR-B and IGF-1R in endometrial physiology and distinct signature in adenocarcinoma. J Clin Endocrinol Metab 101:2883-2891, 2016
60. Huang J, Morehouse C, Streicher K, et al: Altered expression of insulin receptor isoforms in breast cancer. PLoS One 6:e26177, 2011
61. Jiang L, Zhu W, Streicher K, et al: Increased IRA/IR-B ratio in non-small cell lung cancers associates with lower epithelial-mesenchymal transition signature and longer survival in squamous cell lung carcinoma. BMC Cancer 14:131, 2014
62. Allen NE, Key TJ, Appleby PN, et al: Serum insulin-like growth factor (IGF)-I and IGF-binding protein-3 concentrations and prostate cancer risk: Results from the European Prospective Investigation into Cancer and Nutrition. Cancer Epidemiol Biomarkers Prev 16:1121-1127, 2007
63. Renehan AG, Egger M, Minder C, et al: IGF-I, IGF binding protein-3 and breast cancer risk: Comparison of 3 meta-analyses. Int J Cancer 115:1006-1007, author reply 1008, 2005
64. Wolk A, Mantzoros CS, Andersson SO, et al: Insulin-like growth factor 1 and prostate cancer risk: A population-based, case-control study. J Natl Cancer Inst 90:911-915, 1998
65. Rostoker R, Abelson S, Bitton-Worms K, et al: Highly specific role of the insulin receptor in breast cancer progression. Endocr Relat Cancer 22:145-157, 2015
66. Iams WT, Lovly CM: Molecular pathways: Clinical applications and future direction of insulin-like growth factor-1 receptor pathway blockade. Clin Cancer Res 21:4270-4277, 2015
67. 2 and cancer. Endocr Relat Cancer 20:R321-R339, 2013
68. Jeyaratnaganthan N, Højlund K, Kroustrup JP, et al: Circulating levels of insulin-like growth factor-II/mannose-6-phosphate receptor in obesity and type 2 diabetes. Growth Horm IGF Res 20:185-191, 2010
69. Alvino CL, Ong SC, McNeil KA, et al: Understanding the mechanism of insulin and insulin-like growth factor (IGF) receptor activation by IGF-II. PLoS One 6:e27488, 2011
70. Pierre-Eugene C, Pagesy P, Nguyen TT, et al: Effect of insulin analogues on insulin/IGF1 hybrid receptors: Increased activation by glargine but not by its metabolites M1 and M2. PLoS One 7:e41992, 2012
71. Reeve AE: Role of genomic imprinting in Wilms' tumour and overgrowth disorders. Med Pediatr Oncol 27:470-475, 1996
72. 2 imprinting: A potential marker of colorectal cancer risk. Science 299:1753-1755, 2003
73. Steigen SE, Schaeffer DF, West RB, et al: Expression of insulin-like growth factor 2 in mesenchymal neoplasms. Mod Pathol 22:914-921, 2009
74. De Groot JW, Rikhof B, Van Doorn J, et al: Nonislet cell tumour-induced hypoglycaemia: A review of the literature including two new cases. Endocr Relat Cancer 14:979-993, 2007
75. Shaham O, Wei R, Wang TJ, et al: Metabolic profiling of the human response to a glucose challenge reveals distinct axes of insulin sensitivity. Mol Syst Biol 4:214, 2008
76. Cheng Z, Tseng Y, White MF: Insulin signaling meets mitochondria in metabolism. Trends Endocrinol Metab 21:589-598, 2010
77. 76a. Shulman GI: Cellular mechanisms of insulin resistance. J Clin Invest 106:171-6, 2000
78. Pollak M: The insulin and insulin-like growth factor receptor family in neoplasia: An update. Nat Rev Cancer 12:159-169, 2012
79. Moschos SJ, Mantzoros CS: The role of the IGF system in cancer: From basic to clinical studies and clinical applications. Oncology 63:317-332, 2002
80. Mendoza MC, Er EE, Blenis J: The Ras-ERK and PI3K-mTOR pathways: Cross-talk and compensation. Trends Biochem Sci 36:320-328, 2011
81. Pollak M: Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer 8:915-928, 2008
82. Gallagher EJ, Fierz Y, Vijayakumar A, et al: Inhibiting PI3K reduces mammary tumor growth and induces hyperglycemia in a mouse model of insulin resistance and hyperinsulinemia. Oncogene 31:3213-3222, 2012
83. Byers T, Sedjo RL: Does intentional weight loss reduce cancer risk? Diabetes Obes Metab 13:1063-1072, 2011
84. Shaw K, Gennat H, O'Rourke P, et al: Exercise for overweight or obesity. Cochrane Database Syst Rev (4): CD003817, 2006
85. Te Morenga L, Mallard S, Mann J: Dietary sugars and body weight: Systematic review and meta-analyses of randomised controlled trials and cohort studies. BMJ 346:e7492, 2012
86. Leidy HJ, Clifton PM, Astrup A, et al: The role of protein in weight loss and maintenance. Am J Clin Nutr 101:1320S-1329S, 2015
87. Neal EG, Chaffe H, Schwartz RH, et al: The ketogenic diet for the treatment of childhood epilepsy: A randomised controlled trial. Lancet Neurol 7:500-506, 2008
88. Kennedy AR, Pissios P, Otu H, et al: A high-fat, ketogenic diet induces a unique metabolic state in mice. Am J Physiol Endocrinol Metab 292:E1724-E1739, 2007
89. Douris N, Melman T, Pecherer JM, et al: Adaptive changes in amino acid metabolism permit normal longevity inmice consuming a low-carbohydrate ketogenic diet. Biochim Biophys Acta 1852(10 Pt A):2056-2065, 2015
90. Coppola G, Klepper J, Ammendola E, et al: The effects of the ketogenic diet in refractory partial seizures with reference to tuberous sclerosis. Eur J Paediatr Neurol 10:148-151, 2006
91. Fine EJ, Segal-Isaacson CJ, Feinman RD, et al: Targeting insulin inhibition as a metabolic therapy in advanced cancer: A pilot safety and feasibility dietary trial in 10 patients. Nutrition 28:1028-1035, 2012
92. Champ CE, Palmer JD, Volek JS, et al: Targeting metabolism with a ketogenic diet during the treatment of glioblastoma multiforme. J Neurooncol 117:125-131, 2014
93. Rieger J, Bähr O, Maurer GD, et al: ERGO: A pilot study of ketogenic diet in recurrent glioblastoma. Int J Oncol 44:1843-1852, 2014
94. Paoli A, Rubini A, Volek JS, et al: Beyond weight loss: A review of the therapeutic uses of verylowcarbohydrate (ketogenic) diets. Eur J Clin Nutr 67:789-796, 2013
95. Lau YK, Du X, Rayannavar V, et al: Metformin and erlotinib synergize to inhibit basal breast cancer. Oncotarget 5:10503-10517, 2014
96. Kalinsky K, Crew KD, Refice S, et al: Presurgical trial of metformin in overweight and obese patients with newly diagnosed breast cancer. Cancer Invest 32:150-157, 2014
97. Pollak M: Metformin and other biguanides in oncology: Advancing the research agenda. Cancer Prev Res (Phila) 3:1060-1065, 2010
98. Dowling RJ, Niraula S, Chang MC, et al: Changes in insulin receptor signaling underlie neoadjuvant metformin administration in breast cancer: A prospective window of opportunity neoadjuvant study. Breast Cancer Res 17:32, 2015
99. Joerger M, Van Schaik RH, Becker ML, et al: Multidrug and toxin extrusion 1 and human organic cation transporter 1 polymorphisms in patients with castration-resistant prostate cancer receiving metformin (SAKK 08/09). Prostate Cancer Prostatic Dis 18:167-172, 2015
100. Libby G, Donnelly LA, Donnan PT, et al: New users of metformin are at low risk of incident cancer: A cohort study among people with type 2 diabetes. Diabetes Care 32:1620-1625, 2009
101. Higurashi T, Hosono K, Takahashi H, et al: Metformin for chemoprevention of metachronous colorectal adenoma or polyps in post-polypectomy patients without diabetes: A multicentre doubleblind, placebo-controlled, randomised phase 3 trial. Lancet Oncol 17:475-483, 2016
102. Stine JE, Bae-Jump V: Metformin and gynecologic cancers. Obstet Gynecol Surv 69:477-489, 2014
103. Hadad S, Iwamoto T, Jordan L, et al: Evidence for biological effects of metformin in operable breast cancer: A pre-operative, window-of-opportunity, randomized trial. Breast Cancer Res Treat 128:783-794, 2011
104. Niraula S, Dowling RJ, Ennis M, et al: Metformin in early breast cancer: A prospective window of opportunity neoadjuvant study. Breast Cancer Res Treat 135:821-830, 2012
105. DeCensi A, Puntoni M, Guerrieri-Gonzaga A, et al: Effect of metformin on breast ductal carcinoma in situ proliferation in a randomized presurgical trial. Cancer Prev Res (Phila) 8:888-894, 2015
106. Hadad SM, Coates P, Jordan LB, et al: Evidence for biological effects of metformin in operable breast cancer: Biomarker analysis in a pre-operative window of opportunity randomized trial. Breast Cancer Res Treat 150:149-155, 2015
107. Bonanni B, Puntoni M, CazzanigaM, et al: Dual effect of metformin on breast cancer proliferation in a randomized presurgical trial. J Clin Oncol 30:2593-2600, 2012
108. Kalinsky K, Zheng T, Hibshoosh H, et al: Proteomic modulation in breast tumors after metformin exposure: Results from a "window of opportunity" trial. Clin Transl Oncol, 2016
109. Goodwin PJ, Parulekar WR, Gelmon KA, et al: Effect of metformin vs placebo on and metabolic factors in NCIC CTG MA.32. J Natl Cancer Inst 107:djv006, 2015
110. Sivalingam VN, Kitson S, McVey R, et al: Measuring the biological effect of presurgical metformin treatment in endometrial cancer. Br J Cancer 114:281-289, 2016
111. Laskov I, Drudi L, Beauchamp MC, et al: Antidiabetic doses of metformin decrease proliferation markers in tumors of patients with endometrial cancer. Gynecol Oncol 134:607-614, 2014
112. Schuler KM, Rambally BS, DiFurio MJ, et al: Antiproliferative and metabolic effects of metformin in a preoperative window clinical trial for endometrial cancer. Cancer Med 4:161-173, 2015
113. Braghiroli MI, De Celis Ferrari AC, Pfiffer TE, et al: Phase II trial of metformin and paclitaxel for patients with gemcitabine-refractory advanced adenocarcinoma of the pancreas. Ecancermedicalscience 9:563, 2015
114. Kordes S, Pollak MN, Zwinderman AH, et al: Metformin in patients with advanced pancreatic cancer: A double-blind, randomised, placebo-controlled phase 2 trial. Lancet Oncol 16:839-847, 2015
115. Reni M, Dugnani E, Cereda S, et al: (Ir) relevance of metformin treatment in patients with metastatic pancreatic cancer: An open-label, randomized phase II trial. Clin Cancer Res 22:1076-1085, 2016
116. Wink KC, Belderbos JS, Dieleman EM, et al: Improved progression free survival for patients with diabetes and locally advanced non-small cell lung cancer (NSCLC) using metformin during concurrent chemoradiotherapy. Radiother Oncol 118:453-459, 2016
117. Chak A, Buttar NS, Foster NR, et al: Metformin does not reduce markers of cell proliferation in esophageal tissues of patients with Barrett's esophagus. Clin Gastroenterol Hepatol 13:665-672 e1-4, 2015
118. Miranda VC, Braghiroli MI, Faria LD, et al: Phase 2 trial of metformin combined with 5-fluorouracil in patients with refractory metastatic colorectal cancer. Clin Colorectal Cancer: S1533-0028 (16) 30059-7, 2016
119. Tahrani AA, Barnett AH, Bailey CJ: SGLT inhibitors in management of diabetes. Lancet Diabetes Endocrinol 1:140-151, 2013
120. Bendell JC, Rodon J, Burris HA, et al: Phase I, dose-escalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patientswith advanced solid tumors. J Clin Oncol 30:282-290, 2012
121. Hudis C, Swanton C, Janjigian YY, et al: A phase 1 study evaluating the combination of an allosteric AKT inhibitor (MK-2206) and trastuzumab in patients with HER2-positive solid tumors. Breast Cancer Res 15:R110, 2013
122. Jones RL, Kim ES, Nava-Parada P, et al: Phase I study of intermittent oral dosing of the insulin-like growth factor-1 and insulin receptors inhibitor OSI-906 in patients with advanced solid tumors. Clin Cancer Res 21:693-700, 2015
123. Vujic I, Sanlorenzo M, Posch C, et al: Metformin and trametinib have synergistic effects on cell viability and tumor growth in NRAS mutant cancer. Oncotarget 6:969-978, 2015
124. Provinciali N, Lazzeroni M, Cazzaniga M, et al: Metformin: Risk-benefit profile with a focus on cancer. Expert Opin Drug Saf 14:1573-1585, 2015
125. Sos ML, Fischer S, Ullrich R, et al: Identifying genotype-dependent efficacy of single and combined PI3K- and MAPK-pathway inhibition in cancer. Proc Natl Acad Sci USA 106:18351-18356, 2009
126. Bedard PL, Tabernero J, Janku F, et al: A phase Ib dose-escalation study of the oral pan-PI3K inhibitor buparlisib (BKM120) in combination with the oral MEK1/2 inhibitor trametinib (GSK1120212) in patients with selected advanced solid tumors. Clin Cancer Res 21:730-738, 2015
127. Antoun S, Borget I, Lanoy E: Impact of sarcopenia on the prognosis and treatment toxicities in patients diagnosed with cancer. Curr Opin Support Palliat Care 7:383-389, 2013
128. Inagaki J, Rodriguez V, Bodey GP: Proceedings: Causes of death in cancer patients. Cancer 33:568-573, 1974